Shares of TransEnterix, Inc. (NYSEAMERICAN:TRXC) gapped up before the market opened on Monday . The stock had previously closed at $1.18, but opened at $1.05. TransEnterix shares last traded at $1.03, with a volume of 20,306 shares.
A number of equities research analysts recently weighed in on the stock. Piper Jaffray Companies assumed coverage on shares of TransEnterix in a report on Wednesday, May 22nd. They set a “neutral” rating and a $1.60 price objective for the company. BTIG Research upgraded shares of TransEnterix from a “neutral” rating to a “buy” rating and set a $3.00 price target for the company in a report on Tuesday, May 14th. Royal Bank of Canada lowered shares of TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price target for the company. in a report on Thursday. Finally, Zacks Investment Research lowered shares of TransEnterix from a “hold” rating to a “sell” rating in a report on Saturday, July 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $2.62.
TransEnterix (NYSEAMERICAN:TRXC) last released its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $3.64 million for the quarter, compared to analyst estimates of $5.13 million.
TransEnterix Company Profile (NYSEAMERICAN:TRXC)
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Recommended Story: Special Dividends
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.